Rotta Sounds Off On FDA Rejection Of Glucosamine Claim
This article was originally published in The Tan Sheet
Executive Summary
Rotta Pharmaceuticals says FDA made "errors" in its decision to reject a qualified health claim for glucosamine and osteoarthritis
You may also be interested in...
FDA Denies Glucosamine, Chondroitin Osteoarthritis Qualified Health Claim
FDA says there is "no credible scientific evidence" to support proposed health claims linking glucosamine and chondroitin to osteoarthritis (OA), joint degeneration (JD) and cartilage deterioration (CD)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands